Trial reportEBioMedicine2017
Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease.
Trial report in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Sex differences in adult asthma and COPD therapy: a systematic review.Respiratory research · 2022Pooled it
- Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.Respiratory research · 2019Trial
- Sex and Gender in Chronic Obstructive Pulmonary Disease: Does It Matter?Journal of personalized medicine · 2026Review
- Exploring the role of sex in asthma and COPD pharmacological treatment.Current research in pharmacology and drug discovery · 2025Review
- Effect of high-flow nasal oxygen therapy combined with ipratropium bromide on Th1/Th2 balance and inflammation in patients with chronic obstructive pulmonary disease and respiratory failure.Pakistan journal of medical sciences · 2024Article
- Review
- Sex differences in airway disease: estrogen and airway surface liquid dynamics.Biology of sex differences · 2024Review
- Why do we keep ignoring sex in kidney disease?Clinical kidney journal · 2023Review
- Effects of Ipratropium Bromide Combined with Traditional Chinese Medicine Intervention on the Pulmonary Function and Psychological Status of Patients with Chronic Obstructive Pulmonary Disease.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Just breathe: a review of sex and gender in chronic lung disease.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Review
- No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial.ERJ open research · 2020Article
- Sex and gender: modifiers of health, disease, and medicine.Lancet (London, England) · 2020Review
- Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.International journal of chronic obstructive pulmonary disease · 2020Article
- Initiating drug therapy in early stage chronic obstructive pulmonary disease: does it impact the course and outcome?Current opinion in pulmonary medicine · 2019Review
- Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease.American journal of respiratory and critical care medicine · 2018Review
- The mucus bundles responsible for airway cleaning are retained in cystic fibrosis and by cholinergic stimulation.The European respiratory journal · 2018Article
- Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties.Bioscience reports · 2017Review
- Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine.EBioMedicine · 2017Article
- Women manifest more severe COPD symptoms across the life course.International journal of chronic obstructive pulmonary diseaseObservational
Corrections and comments
- Commented on by
Authors and funding
15 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough the prevalence of chronic obstructive pulmonary disease (COPD) is similar between men and women, current evidence used to support bronchodilator therapy has been generated in therapeutic trials that have predominately enrolled male patients. Here, we determined whether there is any significant sex-related differences in FEV
methodsData from the Lung Health Study (n=5887; 37% females) were used to determine changes in FEV
resultsAfter 4months, ipratropium therapy increased FEV
conclusionIpratropium induces a larger bronchodilator response in female than in male patients and the benefits are particularly notable in non-obese females. Female lungs have greater gene expression for the M3 muscarinic receptor relative to M2 receptors than male lungs. Female patients are thus more likely to benefit from ipratropium than male COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.